{"name":"Kali Therapeutics, Inc.","slug":"kali-therapeutics-inc","ticker":"","exchange":"","domain":"kali.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOS05KQVYzOWY0ZVZFSDZZTzZYU25VeTkxNHpCaHdNZWhnUUdkWEFzeEpUajdad1BLckxscFVZNU0yaUx1YjRqSFoxOVQwaHFyVnZ0THR3bzlBUXJadE1xZzlZT0w3YjZ2TVJFRGRibnJVcEQtaEtwTDJKWGJSZ2FXSmlIX1I4REU0VTF6SnBR?oc=5","date":"2026-03-27","type":"pipeline","source":"Medical Marketing and Media","summary":"Rx Rundown: Merck, Gilead Sciences and Sanofi and more - Medical Marketing and Media","headline":"Rx Rundown: Merck, Gilead Sciences and Sanofi and more","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxPOTlGUC1LTXFUTEdRNGhxc01obVc0YUxIU0h4aTBDd0Z3ZTNnMGU2ZnZRQUdVLXl5UEhJWEl3OEc3OU5lR1JPWWtZYVlJYjZjNjJ6WW1MMkh1UGh3UnFmYTB4UDZjbnB0bjNScm9mSFVFbmY0QUNvR2dxaGZiN19kOW5nSnBwOTRfNHFrb3JocVFXUnkyUnpRZ2tLaEdmclBqY014NWw2VHQwOGwybFI2XzhqUldMVDJsTE5zYzFlWHlzcVNyRVNwTEdkNXlkNlBSbHFLYXcxZVJQQmlVVHRvOXlB?oc=5","date":"2026-03-24","type":"deal","source":"European Pharmaceutical Review","summary":"Gilead acquires potential first-in-class T cell engager in $2bn deal with Ouro Medicines - European Pharmaceutical Review","headline":"Gilead acquires potential first-in-class T cell engager in $2bn deal with Ouro Medicines","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxPN2RTWUcyTVN3Tlh6a0owaklCR3VQVW9rUzF1WWs0OXJacVdfNXJ5bF9oMHFBNFZUejlDeFhUeFJPT1B4b1BIY19wTVhQT1cwSzRZTzNmTF9WS3lzSG5ES0NGaFN1OTJVMmZVNFJ0Nm5SOW00bFg2c1BJV2xqSVVlUjU5dWI1QUxwQlZoa1VfOFBVN21kSmY2Wk45NU8zSGpzenhxNDRUQ0V6bWlockRDS1NvZ0dJM1lZbHV2VGhQZ3pMU1VaUDlkOHhPTTM4UGNScEYyS3prWEk?oc=5","date":"2026-03-23","type":"deal","source":"Reuters","summary":"Kali Therapeutics signs deal with Sanofi to develop autoimmune treatment - Reuters","headline":"Kali Therapeutics signs deal with Sanofi to develop autoimmune treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNQU00LXNRNlBCV3ZzTTg5N1FWdVRfaFF1R290YWRPNXUtb2ZkbGc3d0pOU0ZRSU1rMkhRVWhnNDhRSi1ra2RiVkIwV1dBcGNtYWhXWE1qaGtWMk9fdmtaNXRvM1RlWTZKUllUMHlpQkxmZ3MzSmlwa2NVbFVfN1ctTS1nYmM5Z243NDJiMkI2MEV6UU9zNWNyc2tJdThsV1pZZ2V3X3RyaVRrdXM?oc=5","date":"2026-03-23","type":"deal","source":"BioPharm International","summary":"Kali Therapeutics Licenses Tri-Specific T-Cell Engager to Sanofi - BioPharm International","headline":"Kali Therapeutics Licenses Tri-Specific T-Cell Engager to Sanofi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOX3BsYVF5a3hGS1ZJbU1SXzBidDJiZVdpV1VwR0NLVEFWbXYzMngzdW9BYm9VOGtBcHVpSkVDb3NiMlR5RXFBYUI1UW1jdFVNQ2oxMThRU0JHenFybGVWZlpMOXQ0SElGUjVxWlF6Y1B4ZEx6N3hlSjhwYm1tdVA3aVAtb2hBMU5TNV9WMkR4cHNSOWs2OWxFWHV1WnZLVGF0LTh0SzVHVQ?oc=5","date":"2026-03-23","type":"deal","source":"Yahoo Finance","summary":"Kali Therapeutics signs deal with Sanofi to develop autoimmune treatment - Yahoo Finance","headline":"Kali Therapeutics signs deal with Sanofi to develop autoimmune treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxPM1g1MjNjc1dhN1paTGdJaDEtRTR4LWtGaGxYRkJJX3l4NXlNeER5U2VaaWdjdm9WM09fVENWTno0Vm5rZU8xLUZyd3BIVTZyYVZCdURLS0pZVExNaDVrbFpER0ppVTRFUVd6MnhPczRJZHJZQjdXTWxRaHBvbzEwdVpOc205RGNVeTFMZ3VRbjY2WjR4eGljMFhPQ1dxNG14c3ZkbmZST1hhc3hqQzZNNEJxU01oeHduUENNbFRpYWk2NUlxS0h3R3B0clVPdGRvb0dIX1A5UGNJaExzc1dGb240cUtOTElKYnk2S1hBaXM1Q1lsQktLV0pBZ0hEczBpQjRPS3c3MndzTmdSUVoxVjBNd3NjRE5DMHVzcXYxb3NKald0MUpiZTlLVy1DZw?oc=5","date":"2026-03-23","type":"deal","source":"prnewswire.com","summary":"Kali Therapeutics Announces Worldwide Exclusive License Agreement with Sanofi for Next-Generation Tri-Specific T-Cell Engager for Autoimmune Diseases - prnewswire.com","headline":"Kali Therapeutics Announces Worldwide Exclusive License Agreement with Sanofi for Next-Generation Tri-Specific T-Cell En","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxQcGlveU9IejN6MWpVZzZ3VTNTYm1IYXZXZW53aDNNdjJtZTdkelhDNGRTZ2R5Ui1aN3ZvWlhfZlFNcExhd05Cb0F3WEswelNqejBSRnRPbFAyYTZVMjZ3WWU3ZHJCdjRCZEJxUlJSUFJRUmN6Q0k1UVdHaVJRTFpuRFRhSzhsOTFONVpJcmRadS02bC1XRVlnTDU4VzIwdFRFWUZVWVdaWmdmb0JlR2FGaGNMN1BzSm9lVjByQ2xlRW1PY0NvcWsxTlZfbWJ2aTdCdjNvckhySE1hZWU5d0FBRFBNWGwwUEhVTGxqU29uUHdqWWJoY1JV?oc=5","date":"2026-03-18","type":"trial","source":"prnewswire.com","summary":"Kali Therapeutics Announces First Patient Dosed in Phase 1a Clinical Trial of KT501 for Rheumatoid Arthritis - prnewswire.com","headline":"Kali Therapeutics Announces First Patient Dosed in Phase 1a Clinical Trial of KT501 for Rheumatoid Arthritis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOV2RlTnQ3MEdDLTNTYVE0dklXaDNpNlI2MlBDUmhRaVdOUkNzWGp3QkRjZ2dmVndrOG9LbFFvN3VMTlY5eXlYNVQ5MmlnVG1IZ19yZzh3aGQ2clRPSHFIMldXNHAtRW1KU1BWeURJdXdPbmhqQTlVaEVUZTFVQjdmVFpUNXdudllGVlpVSldpaWtuU01ZRF9QTW5tUjZiYVAzUkJvYy1MZGthcVhIZFUweGl0dkVzcFE?oc=5","date":"2025-12-22","type":"deal","source":"European Biotechnology Magazine","summary":"Nine Big Pharma to cut US drug prices in Most-favoured Nations deals - European Biotechnology Magazine","headline":"Nine Big Pharma to cut US drug prices in Most-favoured Nations deals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AJBVV95cUxQeVZNVWFwdEFMaF9XX3ZiXzROaHZzaXdDRzF3azFneThSWFA4T3hzNzd1d2NiY0M5MXFTTW1ONlF2dk1XZUdDcTFtQ0YzXzJuOGtnQXp5U0h1ZnBIN0hURktsbmpaNUgyVTQtUzNLQVdxUk1ZUXhSV3o5YkFwYW5ISFg1WFVtSUtrSWszQmhTTVpwVG8wN3VfZ2ZsWUs4WkxrVGZHbkVUb1RtYm1kaThvNE11RGpmeEt1dklVN2NjQkFKc2duejJ0cGRwMVh4XzJsVWhLSzUzQWtoZmd4cENHVUVNa3RtT2lxQ1g5X0FqbmlxMVdBd3U4azgwb2c3QndTTW1LZ0pLd2NsbGFSenI4aG52dklkRG02LUFtenlyTGNQOXpqQVNiTV83eUZHVG4xbkhSaGtvbk9ITGtUYXR1eGpRVHQ4aVVTU0pfYkJRNUYtSXJpbGZuZ1ZpdTBaR1hZ?oc=5","date":"2025-11-19","type":"trial","source":"businesswire.com","summary":"KaliVir Immunotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate VET3-TGI in Combination with Atezolizumab (Tecentriq®) in Advanced Solid Tumors - business","headline":"KaliVir Immunotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate VET3-TGI i","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAJBVV95cUxPNFhTN3VUb3M3b2JvYk5HcTl2N0M0dXJSTTJidkZHR2NHWWJDc284NjFlSUk2cndOM0V5cGR0NjB3TWlKRXZudkFUeUdROW5LazJzaW1RMjBMWkJsV09KS1c1WXdnbk9WQkdZOFdVM2xfR0ZyTEEtT3pjYjhZekJMNFhfZ05FYmRGMmxWSVQwUGJxVU1VQjRjdnY1aTBqOWd2bWRZdmpZNzlBdWtBR09HdWdFazBUTG41NkJqaDJFR3pQaWlHdHFWTTZPczFyeWM2eHlpSThsMHpfRy1wSnlwOXJJX2g0MW1WbXhiY0hTMDkyZUdudU1CamcyaHNydHI5RzRjZDNZOTNSZUN1eFg3aA?oc=5","date":"2025-05-20","type":"trial","source":"BioSpace","summary":"KaliVir Immunotherapeutics Announces Completion of First Cohort of STEALTH-001 Study Evaluating VET3-TGI in Patients with Advanced Solid Tumors - BioSpace","headline":"KaliVir Immunotherapeutics Announces Completion of First Cohort of STEALTH-001 Study Evaluating VET3-TGI in Patients wit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAJBVV95cUxQM1VHTzF4SUwwUmd3NVlnVGdxMTJoYWZBbFNNN3hnX3VVVVJUVm8tRjdYbGkwSm1tWmF1cmE0NkRwdFFpVTlQeC1GS0JvSm9hOW5UZmtxN3VLRW9rbWNxdEJWQi1BcDRLbzVtOFZ5U3dRd2s0ZGxja3JYc2diVGhFQ2xzMmlnZHdzVElaTTNwYjVDcU9DMjNJdHVValdlUnpKQ0tsWDBXdFpUS1ZUR3l2MGgxR004QzR5SzE1eGxMUC1Jb0tjd3E1V3hXR1pEandUQ3d0LW9hVlUtemtCdzIwb1RBaDBlUXFyVTZvYWF6VWtUVXJaRjdvTFVBVGM4dU5WM3VJOG45TEs0eHNvbl9vaWxtTElZbjdqODVnNg?oc=5","date":"2024-11-18","type":"patent","source":"businesswire.com","summary":"KaliVir Immunotherapeutics Strengthens Innovation Portfolio with Issuance of Three New U.S. Patents Covering Its VET™ Product Candidates - businesswire.com","headline":"KaliVir Immunotherapeutics Strengthens Innovation Portfolio with Issuance of Three New U.S. Patents Covering Its VET™ Pr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxNc3FqT3cwTl9ZQmpwZkFvMmNxSkdLUk5MMzRIN0dmZjRUN2ZYbU9rMUM4cHJ5MUJlOG5PdjBOWHZVLXNTX3A0S2RQTjg5dnVFQzVrNlctMkVYWTloSjNIUklBRjhoSnZhUW5NRUtDbzF5d3FoRVAzeE0zc0kwbHVPdmU2eVdHaVA0LWJEN2NIZ1IyMGRZRG83T19LNHVGV2pZZDFKdFBSNnlWNnNSNV9rOUh2S3h4UHpMck5TMTVnbGpVTnBaZ3kzMm1oOExsMFpTV1dUUE43WThCbktheE95SmtlY1F4NmVPb3c?oc=5","date":"2024-10-08","type":"trial","source":"BioSpace","summary":"KaliVir Immunotherapeutics Doses First Patient in Phase 1/1b Trial of VET3-TGI for Incurable, Advanced, Solid Tumors - BioSpace","headline":"KaliVir Immunotherapeutics Doses First Patient in Phase 1/1b Trial of VET3-TGI for Incurable, Advanced, Solid Tumors","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}